The Ivy Brain Tumor Center (Phoenix) and University of California, San Francisco will partner on a Phase 0 clinical trial to test GSK’s (NYSE:GSK) Zejula in patients with newly diagnosed glioblastoma and recurrent glioma (grades II–IV). Zejula (niraparib) is a daily oral poly (ADP-ribose) polymerase (PARP) inhibitor. FDA introduced Phase 0 clinical trials in 2004…
Ivy Brain Tumor Center sees promise in sonodynamic therapy for glioblastoma
Ivy Brain Tumor Center and its partner Sonalasense have announced positive initial results in a first-in-human Phase 0/1 clinical trial involving recurrent glioblastoma patients. Sonalasense has developed a sonodynamic therapy (SDT) that pairs low-intensity ultrasound with chemotherapeutic agents known as sonosensitizers. The therapy is noninvasive. Data from the trial indicate that SDT swiftly causes targeted…